March 2011.xls by censhunay

VIEWS: 22 PAGES: 1

									                                           Round 14 (March 2011 consideration panels) (28th wave)
                                                                                                                                        Panel
Title                                        Indication                                       ID    Sifting score   Panel score
                                                                                                                                   recommendation
Cancer - 29 March 2011
                                             Soft tissue sarcoma, advanced (second or
Ombrabulin (with cisplatin)                                                                  4726        10             10         Do not progress
                                             third-line)
                                             Lymphoma (follicular, non-Hodgkins)
B-cell lymphoma vaccine                                                                      4837   Confidential    Confidential    Confidential
                                             maintenance
Confidential                                 Myelofibrosis                                   4929        11             13            Progress

Ingenol mebutate gel                         Actinic keratosis – first line                  4932   Confidential    Confidential    Confidential
                                             Hodgkin’s lymphoma – relapsed and / or
SGN-35                                                                                       5031        12             12            Progress
                                             refractory
                                             Systemic anaplastic large cell lymphoma -
SGN-35                                                                                       5032        12             10         Do not progress
                                             relapsed or refractory
                                             Non-small cell lung cancer (NSCLC)
Sorafenib                                    relapsed/refractory advanced - third / fourth   5037        13             10         Do not progress
                                             line
                                             Non-small cell lung cancer, locally
Crizotinib                                   advanced or metastatic (ALK mutation            5116        12             12            Progress
                                             positive) - second or third line
                                             Soft tissue sarcoma, advanced – second
Pazopanib                                                                                    5129        10             10         Do not progress
                                             line
                                             Pleural mesothelioma, advanced malignant
Vorinostat                                                                                   5130        10             11            Progress
                                             – second line
                                             Platinum sensitive ovarian cancer –
Bevacizumab                                                                                  5138        12             13            Progress
                                             second line
                                             Breast cancer metastatic, HER2 positive –
Pertuzumab                                                                                   5139        13             13            Progress
                                             first line
                                             Head and neck cancer, locally advanced,
Nimotuzumab                                                                                  5200        13             10         Do not progress
                                             squamous cell – first line
                                             Pancreatic cancer, locally advanced or
Nimotuzumab with gemcitabine                                                                 5201        13             13            Progress
                                             metastatic – first line
Romidepsin                                   Peripheral T-cell lymphoma –second line         5204        12             12            Progress

Vascular and Metabolic Conditions - 25 March 2011

Confidential                                 Confidential                                    4953        15             N/A        Do not progress
                                             Iron deficiency anaemia in adult patients
Ferumoxytol                                                                                  5023        13             13            Progress
                                             with chronic kidney disease.
                                             Neovascular (wet) age-related macular
VEGF Trap-Eye                                                                                5036        13             14            Progress
                                             degeneration (AMD) – first line
                                             Homozygous and severe heterozygous
Mipomersen                                   familial hypercholesterolaemia (FH) – third     5197        12             14            Progress
                                             or fourth line
Insulin degludec                             Type 1 diabetes                                 5209        13             14            Progress

Insulin degludec                             Type 2 diabetes                                 5210        16             16            Progress
Insulin degludec/insulin aspart              Type 1 diabetes                                 5211        13             13            Progress
Insulin degludec/insulin aspart              Type 2 diabetes                                 5212        16             16            Progress

Acute and Chronic Conditions - 11 March 2011

Pegloticase                                  Chronic gout – second line                      5104        11            11.5        Do not progress

Fidaxomicin                                  Clostridium difficile infection                 5106        13            13.5           Progress
Minimally invasive total hip replacement     For the treatment of worn or damaged hip        5112        12            11.5        Do not progress
                                             joints
Tadalafil                                    Benign prostatic hyperplasia                    5114        15             15            Progress

Alemtuzumab                                  Multiple Sclerosis relapsing remitting          5135        17            14.5           Progress

Dexamethasone intravitreal implant           Non-infectious posterior uveitis                5137        9               9         Do not progress
Sodium oxybate                               Cataplexy in narcolepsy                         5207        14            13.5           Progress

								
To top